세계의 갑상선암 치료제 시장 보고서(2025년)

Thyroid cancer drugs are pharmaceutical agents utilized in the treatment of thyroid cancer. These drugs work by inhibiting various kinase proteins, primarily by preventing the formation of new blood vessels that cancer cells require for growth. They target specific proteins that cancer cells often produce to facilitate their growth. Thyroid cancer typically originates in the thyroid tissue, composed of follicular cells and parafollicular cells.

The main categories of thyroid cancer drugs include radioiodine ablation, thyroid stimulating hormone (TSH) suppression, chemotherapy, targeted multikinase therapy, and other therapeutic approaches. Radioiodine ablation is a form of radiation therapy that employs radioactive iodine to eliminate or ablate any remaining healthy thyroid tissue following a thyroidectomy. Various drugs are used in the treatment of thyroid cancer, including ipilimumab, cabozantinib-s-malate, caprelsa (vandetanib), doxorubicin hydrochloride, lenvatinib mesylate, nivolumab, vandetanib, and others. These drugs find applications in sectors such as hospitals, oncology clinics, research organizations, and others as part of thyroid cancer treatment.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the pharmaceutical sector. Companies are grappling with higher costs on imported active pharmaceutical ingredients (APIs), glass vials, and laboratory equipment-many of which have limited alternative sources. Generic drug manufacturers, already operating with minimal profit margins, are particularly affected, with some scaling back production of low-margin medications. Biotech firms are also experiencing delays in clinical trials due to shortages of specialized reagents linked to tariffs. In response, the industry is shifting API production to regions like India and Europe, building up inventory reserves, and advocating for tariff exemptions on essential medicines.

The thyroid cancer drugs market research report is one of a series of new reports from The Business Research Company that provides thyroid cancer drugs market statistics, including thyroid cancer drugs industry global market size, regional shares, competitors with a thyroid cancer drugs market share, detailed thyroid cancer drugs market segments, market trends and opportunities, and any further data you may need to thrive in the thyroid cancer drugs industry. This thyroid cancer drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The thyroid cancer drugs market size has grown rapidly in recent years. It will grow from $1.16 billion in 2024 to $1.32 billion in 2025 at a compound annual growth rate (CAGR) of 13.6%. The growth in the historic period can be attributed to increasing incidence of thyroid cancer, advances in medical research, favorable regulatory environment, growing healthcare expenditure.

The thyroid cancer drugs market size is expected to see rapid growth in the next few years. It will grow to $2.12 billion in 2029 at a compound annual growth rate (CAGR) of 12.6%. The growth in the forecast period can be attributed to increasing prevalence and aging population, advancements in precision medicine, healthcare infrastructure development, rising awareness and early detection. Major trends in the forecast period include personalized medicine, targeted therapies and immunotherapies, clinical trials and drug pipeline, combination therapies, biomarker-driven treatments, telemedicine and remote monitoring.

The forecast of 12.6% growth over the next five years reflects a modest reduction of 0.5% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions may burden oncology practices by inflating costs of lenvatinib and sorafenib active pharmaceutical ingredients sourced from India and China, potentially reducing differentiated thyroid cancer treatment access and increasing targeted therapy expenses. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The thyroid cancer drugs market is experiencing growth due to the increasing incidences of thyroid cancer, especially in women. For example, in 2022, The American Cancer Society reported approximately 43,800 estimated new cases of thyroid cancer in the United States, with 31,940 cases in women and 11,860 cases in men, leading to 2,230 deaths from thyroid cancer. Among these fatalities, 1,070 are men, and 1,160 are women. This surge in thyroid cancer cases, particularly among women, is a driving force behind the growth of the thyroid cancer drugs market.

The increasing healthcare expenditure is expected to drive the growth of the thyroid cancer drugs market in the coming years. Healthcare expenditure refers to the total spending on healthcare-related goods and services within a specific healthcare system or economy. This expenditure plays a vital role in supporting the development, accessibility, and availability of thyroid cancer drugs. For example, in November 2022, the Canadian Institute for Health Information, a US-based non-profit organization, reported that healthcare spending increased by 0.8%, reaching $331 billion in 2022, compared to 7.6% in 2021. As a result, the rise in healthcare expenditure is fueling the expansion of the thyroid cancer drugs market.

The use of combination drugs in thyroid cancer treatment is growing due to their effectiveness in preventing cancer progression. Combination drugs consist of two or more active pharmaceutical ingredients (APIs) in a single dosage form. These drugs help reduce the development of drug resistance and inhibit the growth of cancer cells. For instance, the FDA approved the combination of dabrafenib (Tafinlar), a BRAF inhibitor, and trametinib (Mekinist), a MEK inhibitor for the treatment of anaplastic thyroid cancer.

Leading companies in the thyroid cancer market are developing innovative products like selpercatinib to enhance treatment options and outcomes for patients. Selpercatinib, sold under the brand name Retevmo, is a medication used to treat various cancers linked to Rearranged During Transfection (RET) mutations, including advanced or metastatic medullary thyroid cancer (MTC) and RET fusion-positive thyroid cancer. For example, in September 2024, Eli Lilly and Company, a US-based pharmaceutical firm, received approval from the U.S. Food and Drug Administration (FDA) for selpercatinib (Retevmo) to treat advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation. This approval applies to both adult and pediatric patients aged 2 years and older who require systemic therapy. This recent approval represents a significant advancement in treatment options for patients with this specific form of thyroid cancer.

In August 2022, Bristol Myers Squibb, a U.S.-based pharmaceutical company, acquired Turning Point Therapeutics for an undisclosed amount. This strategic acquisition expands BMS's portfolio, particularly in the development of precision medicine for cancer patients, including thyroid cancer drugs.

Major companies operating in the thyroid cancer drugs market include Mylan Pharmaceuticals Inc., Alara Pharmaceutical Corporation, Baxter International Inc., Abbott Laboratories, APP Pharmaceuticals LLC, AstraZeneca PLC, GlaxoSmithKline PLC, Exelixis Inc., Novartis AG, Pfizer Inc., Biovista Inc., Vascular Biogenics Ltd., Azaya Therapeutics Inc., Bionomics Limited, Bayer AG, Eisai Co. Ltd., Bio-Path Holdings Inc., Takeda Pharmaceutical Company Limited, AbbVie Inc., Bristol-Myers Squibb Company, Celgene Corporation (a subsidiary of Bristol-Myers Squibb Company), Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Hikma Pharmaceuticals PLC, Ipsen Biopharmaceuticals Inc., Johnson & Johnson, Kyowa Kirin Co. Ltd., Merck & Co. Inc., Sanofi S.A., Amgen Inc., Astellas Pharma Inc., Boehringer Ingelheim International GmbH, Daiichi Sankyo Company Limited, Gilead Sciences Inc., Grifols S.A., Jazz Pharmaceuticals PLC, Mallinckrodt Pharmaceuticals (a subsidiary of Specialty Generics Holdings), Medtronic PLC, Mitsubishi Tanabe Pharma Corporation, Otsuka Pharmaceutical Co. Ltd.

North America was the largest region in the thyroid cancer drugs market in 20242. Middle East is expected to be the fastest-growing region in the thyroid cancer drugs market during the forecast period. The regions covered in the thyroid cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the thyroid cancer drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The thyroid cancer drugs market consists of sales cabozantinib-s-malate, caprelsa, and cometriq. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Thyroid Cancer Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on thyroid cancer drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for thyroid cancer drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The thyroid cancer drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Type: Ipilimumab; Cabozantinib-S-Malate; Caprelsa (Vandetanib); Doxorubicin Hydrochloride; Lenvatinib Mesylate; Nivolumab; Vandetanib; Other Drug Types
• 2) By Type: Radioiodine Ablation; Thyroid Stimulating Hormone (THS) Suppression; Chemotherapy; Targeted Multikinase Therapy; Other Types
• 3) By End Users: Hospitals; Oncology Clinics; Research Organizations; Other End-Users
• Subsegments:
• 1) By Ipilimumab: Monotherapy Ipilimumab; Combination Therapy With Ipilimumab
• 2) By Cabozantinib-S-Malate: Single-Agent Cabozantinib; Combination Therapy With Cabozantinib
• 3) By Caprelsa (Vandetanib): Vandetanib For Medullary Thyroid Cancer (MTC); Combination Therapy With Vandetanib
• 4) By Doxorubicin Hydrochloride: Doxorubicin For Chemotherapy; Liposomal Doxorubicin
• 5) By Lenvatinib Mesylate: Lenvatinib For Differentiated Thyroid Cancer (DTC); Combination Therapy With Lenvatinib
• 6) By Nivolumab: Monotherapy Nivolumab; Combination Therapy With Nivolumab
• 7) By Vandetanib: Single-Agent Vandetanib; Combination Therapy With Vandetanib
• 8) By Other Drug Types: Sorafenib; Everolimus; Pembrolizumab
• Companies Mentioned: Mylan Pharmaceuticals Inc.; Alara Pharmaceutical Corporation; Baxter International Inc.; Abbott Laboratories; APP Pharmaceuticals LLC; AstraZeneca PLC; GlaxoSmithKline plc; Exelixis Inc.; Novartis AG; Pfizer Inc.; Biovista Inc.; Vascular Biogenics Ltd.; Azaya Therapeutics Inc.; Bionomics Limited; Bayer AG; Eisai Co. Ltd.; Bio-Path Holdings Inc.; Takeda Pharmaceutical Company Limited; AbbVie Inc.; Bristol-Myers Squibb Company; Celgene Corporation (a subsidiary of Bristol-Myers Squibb Company); Eli Lilly and Company; F. Hoffmann-La Roche Ltd; Hikma Pharmaceuticals PLC; Ipsen Biopharmaceuticals Inc.; Johnson & Johnson; Kyowa Kirin Co. Ltd.; Merck & Co. Inc.; Sanofi S.A.; Amgen Inc.; Astellas Pharma Inc.; Boehringer Ingelheim International GmbH; Daiichi Sankyo Company Limited; Gilead Sciences Inc.; Grifols S.A.; Jazz Pharmaceuticals plc; Mallinckrodt Pharmaceuticals (a subsidiary of Specialty Generics Holdings); Medtronic plc; Mitsubishi Tanabe Pharma Corporation; Otsuka Pharmaceutical Co. Ltd.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Thyroid Cancer Drugs Market Characteristics

3. Thyroid Cancer Drugs Market Trends And Strategies

4. Thyroid Cancer Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

• 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Thyroid Cancer Drugs Growth Analysis And Strategic Analysis Framework

• 5.1. Global Thyroid Cancer Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Thyroid Cancer Drugs Market Growth Rate Analysis
• 5.4. Global Thyroid Cancer Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Thyroid Cancer Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Thyroid Cancer Drugs Total Addressable Market (TAM)

6. Thyroid Cancer Drugs Market Segmentation

• 6.1. Global Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Ipilimumab
• Cabozantinib-S-Malate
• Caprelsa (Vandetanib)
• Doxorubicin Hydrochloride
• Lenvatinib Mesylate
• Nivolumab
• Vandetanib
• Other Drug Types
• 6.2. Global Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Radioiodine Ablation
• Thyroid Stimulating Hormone (TSH) Suppression
• Chemotherapy
• Targeted Multikinase Therapy
• Other Types
• 6.3. Global Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Oncology Clinics
• Research Organizations
• Other End-Users
• 6.4. Global Thyroid Cancer Drugs Market, Sub-Segmentation Of Ipilimumab, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Monotherapy Ipilimumab
• Combination Therapy With Ipilimumab
• 6.5. Global Thyroid Cancer Drugs Market, Sub-Segmentation Of Cabozantinib-S-Malate, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Single-Agent Cabozantinib
• Combination Therapy With Cabozantinib
• 6.6. Global Thyroid Cancer Drugs Market, Sub-Segmentation Of Caprelsa (Vandetanib), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Vandetanib For Medullary Thyroid Cancer (MTC)
• Combination Therapy With Vandetanib
• 6.7. Global Thyroid Cancer Drugs Market, Sub-Segmentation Of Doxorubicin Hydrochloride, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Doxorubicin For Chemotherapy
• Liposomal Doxorubicin
• 6.8. Global Thyroid Cancer Drugs Market, Sub-Segmentation Of Lenvatinib Mesylate, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Lenvatinib For Differentiated Thyroid Cancer (DTC)
• Combination Therapy With Lenvatinib
• 6.9. Global Thyroid Cancer Drugs Market, Sub-Segmentation Of Nivolumab, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Monotherapy Nivolumab
• Combination Therapy With Nivolumab
• 6.10. Global Thyroid Cancer Drugs Market, Sub-Segmentation Of Vandetanib, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Single-Agent Vandetanib
• Combination Therapy With Vandetanib
• 6.11. Global Thyroid Cancer Drugs Market, Sub-Segmentation Of Other Drug Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Sorafenib
• Everolimus
• Pembrolizumab

7. Thyroid Cancer Drugs Market Regional And Country Analysis

• 7.1. Global Thyroid Cancer Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Thyroid Cancer Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Thyroid Cancer Drugs Market

• 8.1. Asia-Pacific Thyroid Cancer Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Thyroid Cancer Drugs Market

• 9.1. China Thyroid Cancer Drugs Market Overview
• 9.2. China Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Thyroid Cancer Drugs Market

• 10.1. India Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Thyroid Cancer Drugs Market

• 11.1. Japan Thyroid Cancer Drugs Market Overview
• 11.2. Japan Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Thyroid Cancer Drugs Market

• 12.1. Australia Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Thyroid Cancer Drugs Market

• 13.1. Indonesia Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Thyroid Cancer Drugs Market

• 14.1. South Korea Thyroid Cancer Drugs Market Overview
• 14.2. South Korea Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Thyroid Cancer Drugs Market

• 15.1. Western Europe Thyroid Cancer Drugs Market Overview
• 15.2. Western Europe Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Thyroid Cancer Drugs Market

• 16.1. UK Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Thyroid Cancer Drugs Market

• 17.1. Germany Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Thyroid Cancer Drugs Market

• 18.1. France Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Thyroid Cancer Drugs Market

• 19.1. Italy Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Thyroid Cancer Drugs Market

• 20.1. Spain Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Thyroid Cancer Drugs Market

• 21.1. Eastern Europe Thyroid Cancer Drugs Market Overview
• 21.2. Eastern Europe Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Thyroid Cancer Drugs Market

• 22.1. Russia Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Thyroid Cancer Drugs Market

• 23.1. North America Thyroid Cancer Drugs Market Overview
• 23.2. North America Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Thyroid Cancer Drugs Market

• 24.1. USA Thyroid Cancer Drugs Market Overview
• 24.2. USA Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Thyroid Cancer Drugs Market

• 25.1. Canada Thyroid Cancer Drugs Market Overview
• 25.2. Canada Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Thyroid Cancer Drugs Market

• 26.1. South America Thyroid Cancer Drugs Market Overview
• 26.2. South America Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Thyroid Cancer Drugs Market

• 27.1. Brazil Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Thyroid Cancer Drugs Market

• 28.1. Middle East Thyroid Cancer Drugs Market Overview
• 28.2. Middle East Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Thyroid Cancer Drugs Market

• 29.1. Africa Thyroid Cancer Drugs Market Overview
• 29.2. Africa Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Thyroid Cancer Drugs Market Competitive Landscape And Company Profiles

• 30.1. Thyroid Cancer Drugs Market Competitive Landscape
• 30.2. Thyroid Cancer Drugs Market Company Profiles
  • 30.2.1. Mylan Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Alara Pharmaceutical Corporation Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Baxter International Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. APP Pharmaceuticals LLC Overview, Products and Services, Strategy and Financial Analysis

31. Thyroid Cancer Drugs Market Other Major And Innovative Companies

• 31.1. AstraZeneca PLC
• 31.2. GlaxoSmithKline plc
• 31.3. Exelixis Inc.
• 31.4. Novartis AG
• 31.5. Pfizer Inc.
• 31.6. Biovista Inc.
• 31.7. Vascular Biogenics Ltd.
• 31.8. Azaya Therapeutics Inc.
• 31.9. Bionomics Limited
• 31.10. Bayer AG
• 31.11. Eisai Co. Ltd.
• 31.12. Bio-Path Holdings Inc.
• 31.13. Takeda Pharmaceutical Company Limited
• 31.14. AbbVie Inc.
• 31.15. Bristol-Myers Squibb Company

32. Global Thyroid Cancer Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Thyroid Cancer Drugs Market

34. Recent Developments In The Thyroid Cancer Drugs Market

35. Thyroid Cancer Drugs Market High Potential Countries, Segments and Strategies

• 35.1 Thyroid Cancer Drugs Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Thyroid Cancer Drugs Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Thyroid Cancer Drugs Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer